Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
None (25) ·
(none, never marketed) (1) ·
Adderall, Adderall XR, Mydayis (1) ·
Captagon (1) ·
Dalmane (1) ·
Desoxyn (1) ·
Dexedrine (1) ·
Doral (1) ·
Doriden (1) ·
Focalin, Focalin XR (1) ·
Halcion (1) ·
Hetlioz (1) ·
Imovane (1) ·
Lunesta (1) ·
Mogadon (1) ·
Nembutal (1) ·
Placidyl (1) ·
ProSom (1) ·
Quaalude (1) ·
Restoril (1) ·
Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR (1) ·
Rohypnol (1) ·
Rozerem (1) ·
Seconal (1) ·
Sonata (1) ·
THIP (1) ·
Versed (1) ·
Xyrem (1)
classes: (Click arrow to add another value)
mechanism:
None (2) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator (15) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
GABAA positive allosteric modulator; very long half-life (1) ·
GABAA potentiator (1) ·
GABAA potentiator and direct activator (2) ·
GABAB agonist; GHB receptor agonist (1) ·
MAO inhibitor; monoamine releasing agent (1) ·
MAO inhibitor; serotonin releasing agent (1) ·
Melatonin receptor agonist (2) ·
Monoamine releasing agent (4) ·
Monoamine releasing agent, TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport (1) ·
Monoamine releasing agent; 5-HT2A agonist (1) ·
Monoamine releasing agent; serotonergic at higher doses (1) ·
Norepinephrine–dopamine reuptake inhibition (DAT, NET) (1) ·
Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
Prodrug of amphetamine + theophylline (1) ·
Selective GABAA agonist (extrasynaptic delta subunit) (1) ·
Serotonin releasing agent (2) ·
Serotonin releasing agent; 5-HT2A agonist (3) ·
Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) ·
Serotonin/norepinephrine/dopamine releasing agent (3) ·
TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport, net release of dopamine and norepinephrine (1)
uses:
None (47) ·
ADHD, narcolepsy (1) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
'"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1) ·
'"`UNIQ--vote-000004B9-QINU`"', '"`UNIQ--vote-000004BA-QINU`"', '"`UNIQ--vote-000004BB-QINU`"' (1) ·
'"`UNIQ--vote-00000562-QINU`"', '"`UNIQ--vote-00000563-QINU`"', '"`UNIQ--vote-00000564-QINU`"', '"`UNIQ--vote-00000565-QINU`"', '"`UNIQ--vote-00000566-QINU`"' (1)
starting dose:
preparations:
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
None (47) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) ·
Category C (2) ·
Category C (per Desoxyn label) (1) ·
Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion. (1)
legal:
Showing below up to 52 results in range #1 to #52.